June 17, 2015 – SARASOTA, Fla., /PRNewswire/ — Rock Creek Pharmaceuticals, Inc. (NASDAQ: RCPI) (Rock Creek), a drug development company focused on chronic inflammatory disorders, announced today that it has entered into definitive agreements with institutional investors to raise approximately $3.7 million in a registered direct offering of 1,644,500 shares of common stock and warrants to purchase up to 1,223,375 shares of common stock. The shares and warrants will be sold in units, each of which is comprised of one share and 0.75 warrants to purchase one share of common stock. The purchase price per unit in the offering will be $2.25. The warrants will be exercisable six months following the date of issuance and will expire on the fifth anniversary of the initial date that the warrants become exercisable. The warrants will have an exercise price of $2.83. The offering is expected to close on or about June 19, 2015, subject to customary closing conditions.
Maxim acted as a sole placement agent for Rock Creek Pharmaceuticals, Inc.’s $3.7 million registered direct.